127 related articles for article (PubMed ID: 16609149)
1. Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.
Rodriguez WE; Tyagi N; Joshua IG; Passmore JC; Fleming JT; Falcone JC; Tyagi SC
Am J Physiol Renal Physiol; 2006 Sep; 291(3):F694-701. PubMed ID: 16609149
[TBL] [Abstract][Full Text] [Related]
2. Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
Sen U; Rodriguez WE; Tyagi N; Kumar M; Kundu S; Tyagi SC
Am J Physiol Endocrinol Metab; 2008 Nov; 295(5):E1205-12. PubMed ID: 18780770
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus.
Rodriguez WE; Joshua IG; Falcone JC; Tyagi SC
Am J Physiol Heart Circ Physiol; 2006 Jul; 291(1):H81-7. PubMed ID: 16489101
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.
Majithiya JB; Paramar AN; Balaraman R
Cardiovasc Res; 2005 Apr; 66(1):150-61. PubMed ID: 15769458
[TBL] [Abstract][Full Text] [Related]
5. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats.
Dong FQ; Li H; Cai WM; Tao J; Li Q; Ruan Y; Zheng FP; Zhang Z
Chin Med J (Engl); 2004 Jul; 117(7):1040-4. PubMed ID: 15265379
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
Huang PH; Sata M; Nishimatsu H; Sumi M; Hirata Y; Nagai R
Biomed Pharmacother; 2008 Jan; 62(1):46-52. PubMed ID: 17692499
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
Baylis C; Atzpodien EA; Freshour G; Engels K
J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039
[TBL] [Abstract][Full Text] [Related]
10. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats.
Schwartz D; Schwartz IF; Blantz RC
J Lab Clin Med; 2001 Feb; 137(2):107-14. PubMed ID: 11174467
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet.
Murthy SN; Obregon DF; Chattergoon NN; Fonseca NA; Mondal D; Dunne JB; Diez JG; Jeter JR; Kadowitz PJ; Agrawal KC; McNamara DB; Fonseca VA
Metabolism; 2005 May; 54(5):645-52. PubMed ID: 15877295
[TBL] [Abstract][Full Text] [Related]
12. Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice.
Maehira F; Ishimine N; Miyagi I; Eguchi Y; Shimada K; Kawaguchi D; Oshiro Y
Nutrition; 2011 Apr; 27(4):488-95. PubMed ID: 20708379
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
14. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats.
Koike T; Tomoda F; Kinuno H; Inoue H; Takata M
Acta Physiol Scand; 2005 May; 184(1):73-81. PubMed ID: 15847646
[TBL] [Abstract][Full Text] [Related]
15. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice.
Ohshiro Y; Ma RC; Yasuda Y; Hiraoka-Yamamoto J; Clermont AC; Isshiki K; Yagi K; Arikawa E; Kern TS; King GL
Diabetes; 2006 Nov; 55(11):3112-20. PubMed ID: 17065350
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer.
Cox MJ; Hawkins UA; Hoit BD; Tyagi SC
Circulation; 2004 May; 109(17):2123-8. PubMed ID: 15117845
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.
Cao Z; Ye P; Long C; Chen K; Li X; Wang H
Pharmacology; 2007; 79(3):184-92. PubMed ID: 17356310
[TBL] [Abstract][Full Text] [Related]
18. Effect of aspirin on experimental diabetic nephropathy.
Moel DI; Safirstein RL; McEvoy RC; Hsueh W
J Lab Clin Med; 1987 Sep; 110(3):300-7. PubMed ID: 3475395
[TBL] [Abstract][Full Text] [Related]
19. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.
Tuttle KR; Bruton JL; Perusek MC; Lancaster JL; Kopp DT; DeFronzo RA
N Engl J Med; 1991 Jun; 324(23):1626-32. PubMed ID: 2030719
[TBL] [Abstract][Full Text] [Related]
20. The kidney expression of matrix metalloproteinase-9 in the diabetic nephropathy of Kkay mice.
Qing-Hua G; Ju-Ming L; Chang-Yu P; Zhao-Hui L; Xiao-Man Z; Yi-Ming M
J Diabetes Complications; 2008; 22(6):408-12. PubMed ID: 18413157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
